StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) operating KPIs

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)

Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%

Gilead Sciences arcus Biosciences — Total liabilities (legacy XBRL tag, $M) ($M)

Arcus Biosciences (RCUS) Form 10-Q / 10-K

QuarterlyAnnual
Latest, Q3 2022
695
Period ended Sep 30, 2022
Change on a year earlier
+134.3%
297 in Q3 2021
History
15 quarters
Since Q1 2019
Sources
14
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedArcus Biosciences — Total liabilities (legacy XBRL tag, $M) ($M)Year on yearSource
Q3 2022Sep 30, 2022695+134.3%SEC Filing ↗
Q2 2022Jun 30, 2022729+147.9%SEC Filing ↗
Q1 2022Mar 31, 2022747+176.3%SEC Filing ↗
Q4 2021Dec 31, 2021751+178.0%SEC Filing ↗
Q3 2021Sep 30, 2021297+11.2%SEC Filing ↗
Q2 2021Jun 30, 2021294+458.3%SEC Filing ↗
Q1 2021Mar 31, 2021270+661.4%SEC Filing ↗
Q4 2020Dec 31, 2020270+587.0%SEC Filing ↗
Q3 2020Sep 30, 2020267+571.8%SEC Filing ↗
Q2 2020Jun 30, 202052.7+24.6%SEC Filing ↗
Q1 2020Mar 31, 202035.5-4.1%SEC Filing ↗
Q4 2019Dec 31, 201939.3–SEC Filing ↗
Q3 2019Sep 30, 201939.7–SEC Filing ↗
Q2 2019Jun 30, 201942.3–SEC Filing ↗
Q1 2019Mar 31, 201937–SEC Filing ↗

Cite this data

StockData. (2026). Gilead Sciences Arcus Biosciences — Total liabilities (legacy XBRL tag, $M) ($M), quarterly Q1 2019–Q3 2022 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus_liab_tot

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.